Adding the TKI cediranib to chemotherapy improved progression-free survival in patients with metastatic or relapsed cervical cancer, according to a study presented at the 2014 ESMO Congress.
STAT3 inhibition using a novel compound restored sensitivity to TKIs in CML cells that had shown resistance independent of BCR-ABL1 kinase activity.
A new study sheds light on the prevalence of ALK positive non–small-cell lung cancer and suggests the best methods for screening.
The addition of ramucirumab to docetaxel improved outcomes over placebo with docetaxel as a second-line treatment of patients with advanced non-small-cell lung cancer (NSCLC), according to results of the REVEL trial.
The addition of bevacizumab to erlotinib as first-line therapy yielded a significantly extended progression-free survival in patients with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC), according to a new phase II study.
The addition of the anti-EGFR antibody necitumumab to gemcitabine-cisplatin chemotherapy resulted in a modest but significant benefit to patients with stage IV squamous cell non-small-cell lung cancer, according to results of the SQUIRE study presented at ASCO.
Ibrutinib substantially increased progression-free survival and overall survival over ofatumumab in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), according to the results of the RESONATE trial.
The addition of the MET-targeting antibody onartuzumab to erlotinib added no benefit, and may have been detrimental, to patients with MET-amplified stage IIIb/IV metastatic non–small-cell lung cancer, according to a new phase III trial.
A novel agent known as AZD9291 showed promising results in a phase I dose escalation trial among non-small-cell lung cancer (NSCLC) patients whose disease progresses after treatment with EGFR-targeting tyrosine kinase inhibitors.
The new drug volasertib, which is in trials for the treatment of patients with acute myeloid leukemia (AML), has been granted orphan drug designation by the FDA.